Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Targets. 2011 Mar;15(3):351-3. doi: 10.1517/14728222.2011.550880. Epub 2011 Jan 5.

Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.

Author information

  • University of Medicine and Pharmacy Gr.T.Popa Iasi, Pulmonary Disease University Hospital, Department of Internal Medicine II-Pulmonary Disease, 30 Dr I Cihac Str, 700115 Iasi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro

Abstract

INTRODUCTION:

In lung adenocarcinoma, certain mutations such as echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) are associated with lower sensitivity to chemotherapy, when used conventionally as the first-line therapy in the advanced stage of the disease.

AREAS COVERED:

This paper discusses the clinical and therapeutic importance of ALK mutations in NSCLC and the early clinical results of a Phase I study assessing crizotinib in patients with ALK mutations.

EXPERT OPINION:

Abnormal ALK is evolving as an important therapeutic target in patients with more aggressive lung adenocarcinoma. Further clinical studies are needed in order to assess if crizotinib, an ALK inhibitor, is able to increase the efficacy of the conventional chemotherapy in this disease subset.

Comment on

PMID:
21208134
[PubMed]

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk